Mini Review ARTICLE
Algae-based oral recombinant vaccines
- California Center for Algae Biotechnology, University of California at San Diego, La Jolla, CA, USA
Recombinant subunit vaccines are some of the safest and most effective vaccines available, but their high cost and the requirement of advanced medical infrastructure for administration make them impractical for many developing world diseases. Plant-based vaccines have shifted that paradigm by paving the way for recombinant vaccine production at agricultural scale using an edible host. However, enthusiasm for “molecular pharming” in food crops has waned in the last decade due to difficulty in developing transgenic crop plants and concerns of contaminating the food supply. Microalgae could be poised to become the next candidate in recombinant subunit vaccine production, as they present several advantages over terrestrial crop plant-based platforms including scalable and contained growth, rapid transformation, easily obtained stable cell lines, and consistent transgene expression levels. Algae have been shown to accumulate and properly fold several vaccine antigens, and efforts are underway to create recombinant algal fusion proteins that can enhance antigenicity for effective orally delivered vaccines. These approaches have the potential to revolutionize the way subunit vaccines are made and delivered – from costly parenteral administration of purified protein, to an inexpensive oral algae tablet with effective mucosal and systemic immune reactivity.
Infectious diseases directly account for nearly 25% of deaths worldwide, and are a predominant cause of morbidity and mortality in the developing world (Fauci et al., 2005). Even for diseases for which vaccines exist, limited access – due to financial as well as infrastructural or medical personnel limitations – is a major contributor to this high infectious disease burden. Many developing world diseases do not yet have vaccines, in part because traditional vaccine production costs present a significant investment hurdle, considering the financial capacity of the intended consumers. Both cost and ease of administration are challenges that must be tackled to address this undue burden on global health and productivity.
Oral vaccination has many distinct advantages over parenteral administration, but has proven difficult to achieve thus far, reflected by the scarcity of licensed oral vaccines. Perhaps the most significant benefit of oral vaccination is the ability to elicit both mucosal and systemic immunity. As most human pathogens enter via mucosal surfaces – either nasally, orally, or by sexual transmission – mucosal immunity can serve as a first line of defense to prevent infection before it reaches the bloodstream (Mason and Herbst-Kralovetz, 2012). Oral vaccines also obviate the need for trained medical personnel to administer them and reduce the risks of infection associated with needles. They also have higher compliance from patients, owing to the lack of fear and resistance associated with injections. Both of these latter aspects are important considerations for successful vaccination campaign coverage in remote or resource-limited settings.
Plant-produced vaccines have two critical advantages: much lower cost than traditional recombinant vaccine platforms, and improved safety because of insusceptibility to mammalian pathogen contamination. The batch costs of plant-produced vaccines may be as much as a thousand times less than traditional animal cell culture or even bacterial or yeast cell culture, though it has been noted that this will not translate directly to per-dose cost because downstream sales, packaging, and distribution costs are similar regardless of production method (Rybicki, 2009). The current status of plant-produced vaccines in pre-clinical and early phase human clinical trials has been extensively reviewed (Lossl and Waheed, 2011; Mason and Herbst-Kralovetz, 2012; Rosales-Mendoza et al., 2012a,b; Guan et al., 2013; Jacob et al., 2013); despite positive preliminary data, none have made it through to licensing. The only licensed plant-produced vaccine is a veterinary injectable vaccine against Newcastle disease virus in poultry, made from purified antigen expressed in cultured tobacco cells. Dow AgroSciences received Food and Drug Administration (FDA) approval for the vaccine in 2006, but only as a demonstration that plant-produced vaccines can meet the stringent regulatory requirements for approval; it is not currently for sale (Rybicki, 2009).
Plant cells are of particular interest for oral vaccines because their rigid cell walls provide exceptional antigen protection through the stomach into the intestines, where they can access the gut-associated lymphoid tissue (Kwon et al., 2013). Expression within chloroplasts or other storage organelles may also provide additional protection (Khan et al., 2012). While vaccine antigens have been transformed into many edible species including lettuce, tomato, potato, and tobacco, expression in stable transformed crop plants has suffered from low yields, typically less than 1% of total soluble protein (TSP; Lossl and Waheed, 2011). Yields have been increased by transient expression using recombinant viral vectors or Agrobacterium infection, but this expression is typically unstable (Rybicki, 2009). Even using these strategies, the most consistently high-yielding host species is tobacco, which is inedible and therefore would require purification prior to vaccine administration (Lossl and Waheed, 2011).
Algae as a Recombinant Protein Production Platform
Green microalgae have proven to be highly useful protein production platforms for a variety of industrial and therapeutic applications, particularly for complex or heavily disulfide-bonded proteins. The chloroplast provides a unique enclosed compartment that facilitates folding (Chebolu and Daniell, 2009), and transgene products have been shown to accumulate to high levels in the algal chloroplast – as high as 10% of TSP (Manuell et al., 2007; Surzycki et al., 2009). Unlike prokaryotes, chloroplasts of algae contain much of the same sophisticated cellular folding machinery as other eukaryotic organisms like yeast. While the algal nuclear genome can also be transformed, to date most transgene expression has been from the chloroplast genome due to reduced gene silencing and higher protein accumulation.
The green alga model organism Chlamydomonas reinhardtii has been used to produce a number of human and animal therapeutically relevant proteins, including full-length human antibodies (Tran et al., 2009), signaling molecules such as vascular endothelial growth factor (Rasala et al., 2010), and structural proteins like fibronectin (Rasala et al., 2010). Though expression levels are highly variable by gene, improvements in codon optimization (Franklin et al., 2002; Surzycki et al., 2009) and characterization of ideal gene regulatory elements (Rasala et al., 2011; Specht and Mayfield, 2013) continue to increase levels of transgene expression. C. reinhardtii’s success and future potential as a therapeutic protein production platform has been recently reviewed (Rasala and Mayfield, 2011).
Advantages of an Algal Vaccine Production Host
Unicellular green algae possess all the positive attributes of plant systems, plus several unique advantages over terrestrial plants as vaccine production hosts. Algal biomass accumulation is extremely rapid, and the entirety of the biomass can be utilized for vaccine production, unlike plants that expend energy producing supporting tissues that do not contain the vaccine antigen or cannot be harvested easily. Algae are also not restricted by growing season or local soil fertility, and concerns of cross-contamination of nearby food crops are non-existent. Enclosed bioreactors can be used for higher biomass yields and to reduce concerns of environmental escape (Franconi et al., 2010), and media can be recycled to minimize water and nutrient loss. The 2002 discovery of transgenic viral capsid protein-expressing maize in food harvests of nearby corn and soybean crops effectively halted efforts to produce vaccines in edible crop plants, making a food crop-based oral vaccine highly unlikely (Rybicki, 2009). Green algae such as C. reinhardtii are generally recognized as safe (GRAS) by the FDA, resurrecting hope that unprocessed edible vaccines can be produced in a photosynthetic organism.
Crop plants can contain hundreds of chloroplasts per cell, and each chloroplast harbors dozens of copies of its plastid genome. In contrast, C. reinhardtii contains a single chloroplast that occupies about half of the volume of the cell (Franklin and Mayfield, 2005), making stable homoplasmic transformed lines much easier to obtain (a few weeks versus several months) and allowing for increased yields of plastid-expressed vaccine antigens, which account for nearly all antigens expressed to date in algae. This genomic stability, combined with the ability to tightly regulate growth conditions inside contained bioreactors, allows for more consistent expression levels than terrestrial plants, which can vary by several-fold.
Finally, algae can be easily preserved by lyophilization, and two studies of algal-produced vaccine antigens have verified that dried algae stored at room temperature for 6 months (Gregory et al., 2013) or even 20 months (Dreesen et al., 2010) exhibit nearly equivalent antigen effectiveness as freshly harvested algae, though storage at 37° did begin to cause a loss of activity over time (Gregory et al., 2013). The algal cell wall appears sufficient to withstand harsh conditions within the stomach, as very little antigen degradation was observed after whole cells were incubated with pepsin at pH 1.7 (Dreesen et al., 2010). These observations indicate that algae are an ideal host for vaccine transport without cold-chain supply, and that the cells provide adequate protection for antigens en route to the intestinal mucosal lymph tissue, obviating the additional expense associated with encapsulation.
Algal Vaccine Progress
The first reported algal-synthesized vaccine antigen was a chimeric molecule comprising the foot-and-mouth disease virus structural protein VP1 and the beta subunit of cholera toxin (CTB), a known mucosal adjuvant (Sun et al., 2003). This antigen had been previously expressed in plants and had demonstrated oral immunity in mice (Wigdorovitz et al., 1999), but advancement of trials was hindered by low expression levels. In C. reinhardtii, 3–4% TSP was reported, but higher yields may be possible because the strains examined were not completely homoplasmic (Sun et al., 2003).
The next report of an algal-produced vaccine antigen showed the first in vivo data for efficacy conferring immunity. The classical swine fever virus (CSFV) surface protein E2 was expressed from the C. reinhardtii chloroplast genome, and total protein extracts were administered subcutaneously with Freud’s adjuvant or orally by gavage with no adjuvant. Subcutaneous immunization reportedly induced a significant immune response, but no data for this result was shown. No systemic or mucosal immune response was detected after the oral immunization, and it was suggested that a mucosal adjuvant may be necessary for oral administration to be effective (He et al., 2007).
Wang et al. (2008) expressed the human glutamic acid decarboxylase, a known Type 1 diabetes autoimmune antigen, which reacted with sera from non-obese diabetic mice. Surprisingly, detectable expression was achieved using a non-codon-optimized gene. A more thorough investigation of the factors affecting vaccine antigen expression in algae found that indeed codon optimization is critical for high yield. It has also been noted that yield is highly variable among individual transformants despite the fact that chloroplast transformation proceeds by homologous recombination, eliminating positional effects within the genome (Surzycki et al., 2009).
Oral immunization was finally shown to be effective when the antigen of interest was fused to the B subunit of CTB, which forms a pentameric structure and binds the GM1 ganglioside for internalization into intestinal cells. After feeding freeze-dried algae repeatedly to mice, fecal IgA and systemic IgG antibody titers reached similarly high levels for both the intended Staphylococcus aureus antigen and CTB. Significantly, within a week of finishing the 5-week oral vaccination, 80% of immunized mice survived a lethal challenge with S. aureus that killed all control mice within 48 h (Dreesen et al., 2010).
Two studies earlier this year reported relatively low yields of two additional algal-produced antigens, but they are still promising compared to previous literature using alternative systems. A human papillomavirus E7 protein, while only accumulated to 0.12% TSP, expressed similar to or better than in other plant systems and did not require fusion to a stabilizing protein to achieve consistent expression. Furthermore, the algal chloroplast-produced E7 was soluble, whereas the plant-produced E7 was found predominantly in the insoluble fraction using multiple solubilization buffers. While the antibody titer elicited by affinity purified protein was much higher, a crude algal extract was shown to be equally effective at preventing tumor development and promoting mouse survival (Demurtas et al., 2013). A chimeric antigen intended to prevent hypertension, consisting of a fusion between angiotensin and a Hepatitis B antigen as a carrier, was the first algal vaccine to be expressed from the nuclear genome without chloroplast targeting. While it only accumulated to 0.05% TSP, it was detectable by Western blot from algal TSP extracts (Soria-Guerra et al., 2014).
Since 2010, several studies have shown that malarial transmission-blocking vaccines can be produced in C. reinhardtii. Transmission-blocking vaccines target surface proteins that appear on the sexual and gamete stages of Plasmodium, the causative pathogen of malaria. There is some evidence that these vaccines may provide partial protection to individuals, but the main benefit of vaccination with a transmission-blocking vaccine is derived from herd immunity preventing the spread of the disease. Therefore, it is especially critical that transmission-blocking vaccines can be delivered easily and at extremely low cost, to reach threshold coverage of the huge populations living in malaria-endemic regions. One difficulty of producing these Plasmodium surface proteins is that they contain multiple EGF-like domains that are heavily disulfide-bonded, rendering them difficult to fold and therefore difficult to accumulate to high levels without forming insoluble aggregates (Gregory et al., 2012). Interestingly, Plasmodia appear to not glycosylate their proteins (Gowda and Davidson, 1999), making algal chloroplasts suitable hosts as the chloroplast also does not contain glycosylation machinery.
A total of six algae-produced malarial antigens or fragments thereof – Pfs25, Pfs28, Pfs48/45, PfMSP1, PbMSP1, and PbAMA1 – have been shown to fold properly and exhibit antibody recognition akin to that of the native Plasmodium surface proteins (Dauvillée et al., 2010; Gregory et al., 2012; Jones et al., 2013). Algal chloroplast-produced Pfs25 was able to completely prevent malaria transmission, indicated by a total absence of Plasmodium oocysts in mosquito midguts after feeding on immunized mouse sera. Furthermore, feeding lyophilized algae expressing Pfs25 fused to CTB elicited a mucosal response to both antigens (Gregory et al., 2013). However, systemic IgG response was only observed for the CTB. This is in contrast with the S. aureus D2 protein fused to CTB, where systemic immunity was elicited for both domains (Dreesen et al., 2010), suggesting that either the furin protease cleavable linker between the Pfs25 and CTB domains prevented Pfs25 from being presented to the systemic immune system, or perhaps that Pfs25 is inherently less immunogenic. In a different strategy, truncated versions of the malarial proteins AMA1 and MSP1 were fused to the major protein constituent of the chloroplast starch granules, the granule-bound starch synthase (GBSS). Though they were expressed from the nuclear genome, reasonable accumulation was achieved because the proteins were targeted to and sequestered within the chloroplast starch granules. Both oral and injected vaccination using purified starch from these strains reduced parasite load and prolonged mice survival after challenge with Plasmodium berghei; in the case of an injected vaccine consisting of both antigens, 30% of mice survived the otherwise-lethal infection (Dauvillée et al., 2010).
All vaccines produced in algae to date are summarized in Table 1, along with reported yields and significant pre-clinical findings. Most work thus far has been performed in the green alga model organism C. reinhardtii, though one of the earliest reports of an algal-produced hepatitis B antigen was in the marine alga Dunaliella salina (Geng et al., 2003) and hepatitis B antigen has also been produced in the diatom Phaeodactylum tricornutum (Hempel et al., 2011). In recent years the algal genetic toolkit has been expanded to other algal species, including other green algae, diatoms, and cyanobacteria (Ducat et al., 2011; Georgianna and Mayfield, 2012; Qin et al., 2012), with a goal of broad host range compatibility. Already, over 20 species of algae – including dinoflagellates, red algae, and diatoms – have been transformed, and a suite of promoters and selectable markers have been characterized for many species (see Gong et al., 2011, for a comprehensive review). While the first generation of algal vaccines has been predominantly pioneered in Chlamydomonas, these advances can readily be applied to alternative algal species that may be more suitable for large-scale vaccine production.
Future Potential for Algal-Based Oral Recombinant Vaccines
From the research available to date, it is clear that algae can produce complex vaccine antigens, and that Chlamydomonas-produced antigens can elicit immunogenic responses that are appropriate for their intended roles as vaccines. It is also clear that identifying alternative mucosal adjuvants to complement these antigens is critical, whether for co-administration with algal-produced antigens or for incorporation into chimeric fusion proteins. It has been suggested that antigenic fusions with CTB, one of the preferred adjuvants, may interfere with the CTB subunit’s ability to form the pentameric structure essential for strong GM1 ganglioside binding (Sun et al., 2003). Many alternatives to CTB are under investigation for oral vaccination in other production platforms, including CpG-containing oligodeoxynucleotides, saponins, and subunits from heat-labile enterotoxin and ricin toxin (Pelosi et al., 2012). Future work should empirically explore many combinations of antigens, mucosal adjuvants, and even testing multiple linkers and potential translocation domains. As has been noted previously, expression, uptake, and antigenicity are all difficult to predict in the context of plant-produced oral vaccine antigens (Rybicki, 2009), so a high-throughput system like algae is extremely valuable for rapidly testing many versions of potential chimeric vaccine molecules. Furthermore, many antigens will require proper post-translational modifications such as glycosylation to be recognized properly; more work needs to be done to increase expression levels from the nuclear genome, as glycosylation does not occur in the chloroplast.
It has been suggested that the first licensed plant-produced human vaccines likely will not be the first ones tested in humans, many of which targeted pathogens like Hepatitis B for which a relatively inexpensive vaccine already exists (Rybicki, 2009). Stepping stones along the way to human vaccines may include reagents for cheaper diagnostics and development of veterinary vaccines. Several human studies with plant-made vaccines have also indicated a role for oral boosting of an existing immune response conferred by traditional injectable vaccines (Mason and Herbst-Kralovetz, 2012). An algal-produced human vaccine production platform will likely come to fruition as an alternative for very expensive vaccines like HPV, or for novel vaccines against diseases for which no alternative currently exists (Martinez et al., 2012). The cost and logistical considerations of storage, delivery, and administration in resource-limited settings indicate that plant or algal production may be the only feasible option for large-scale inexpensive vaccination, and thus this avenue deserves increased attention from research funding agencies and investment from the pharmaceutical industry as well.
Elizabeth A. Specht and Stephen P. Mayfield wrote and revised the manuscript. Elizabeth A. Specht developed Table 1.
Conflict of Interest Statement
The author Stephen P.Mayfield declares a financial interest in Triton Animal Health, a company making orally available nutritional supplements, and potentially orally available vaccines, should these prove to be biologically functional.
This work was funded by a Department of Energy, Consortium for Algal Biofuels Commercialization grant, DE-EE0003373; and by the California Energy Commission, California Initiative for Sustainable Large Molecule Fuels, 500–10–039. Elizabeth A. Specht was supported by a National Science Foundation graduate research fellowship. We thank Prema Karunanithi for her careful proofreading of the manuscript.
Chebolu, S., and Daniell, H. (2009). “Chloroplast-derived vaccine antigens and biopharmaceuticals: expression, folding, assembly and functionality,” in Plant-Produced Microbial Vaccines, ed. A.V. Karasev. (Berlin: Springer-Verlag Berlin), 33–54. doi: 10.1007/978-3-540-70868-1_3
Dauvillée, D., Delhaye, S., Gruyer, S., Slomianny, C., Moretz, S. E., D’Hulst, C., et al. (2010). Engineering the chloroplast targeted malarial vaccine antigens in Chlamydomonas starch granules. PLoS ONE 5:e15424. doi: 10.1371/journal.pone.0015424
Demurtas, O. C., Massa, S., Ferrante, P., Venuti, A., Franconi, R., and Giuliano, G. (2013). A Chlamydomonas-derived human papillomavirus 16 E7 vaccine induces specific tumor protection. PLoS ONE 8:e61473. doi: 10.1371/journal.pone.0061473
Dreesen, I. A., Charpin-El Hamri, G., and Fussenegger, M. (2010). Heat-stable oral alga-based vaccine protects mice from Staphylococcus aureus infection. J. Biotechnol. 145, 273–280. doi: 10.1016/j.jbiotec.2009.12.006
Fauci, A. S., Touchette, N. A., and Folkers, G. K. (2005). Emerging infectious diseases: a 10-year perspective from the national institute of allergy and infectious diseases. Emerg. Infect. Dis. 11, 519–525. doi: 10.3201/eid1104.041167
Franklin, S. E., and Mayfield, S. P. (2005). Recent developments in the production of human therapeutic proteins in eukaryotic algae. Expert Opin. Biol. Ther. 5, 225–235. doi: 10.1517/14712522.214.171.124
Franklin, S., Ngo, B., Efuet, E., and Mayfield, S. P. (2002). Development of a GFP reporter gene for Chlamydomonas reinhardtii chloroplast. Plant J.Cell Mol. Biol. 30, 733–744. doi: 10.1046/j.1365-313X.2002.01319.x
Geng, D. G., Wang, Y. Q., Wang, P., Li, W. B., and Sun, Y. R. (2003). Stable expression of hepatitis B surface antigen gene in Dunaliella salina (Chlorophyta). J. Appl. Phycol. 15, 451–456. doi: 10.1023/B:JAPH.0000004298.89183.e5
Gong, Y., Hu, H., Gao, Y., Xu, X., and Gao, H. (2011). Microalgae as platforms for production of recombinant proteins and valuable compounds: progress and prospects. J. Ind. Microbiol. Biotechnol. 38, 1879–1890. doi: 10.1007/s10295-011-1032-6
Gregory, J. A., Li, F., Tomosada, L. M., Cox, C. J., Topol, A. B., Vinetz, J. M., et al. (2012). Algae-produced Pfs25 elicits antibodies that inhibit malaria transmission. PLoS ONE 7:e37179. doi: 10.1371/journal.pone.0037179
Gregory, J. A., Topol, A. B., Doerner, D. Z., and Mayfield, S. (2013). Alga-produced cholera toxin-pfs25 fusion proteins as oral vaccines. Appl. Environ. Microbiol. 79, 3917–3925. doi: 10.1128/AEM.00714-13
Guan, Z. J., Guo, B., Huo, Y. L., Guan, Z. P., Dai, J. K., and Wei, Y. H. (2013). Recent advances and safety issues of transgenic plant-derived vaccines. Appl. Microbiol. Biotechnol. 97, 2817–2840. doi: 10.1007/s00253-012-4566-2
He, D. M., Qian, K. X., Shen, G. F., Zhang, Z. F., Li, Y. N., Su, Z. L., et al. (2007). Recombination and expression of classical swine fever virus (CSFV) structural protein E2 gene in Chlamydomonas reinhardtii chroloplasts. Colloids Surf. B Biointerfaces 55, 26–30. doi: 10.1016/j.colsurfb.2006.10.042
Hempel, F., Lau, J., Klingl, A., and Maier, U. G. (2011). Algae as protein factories: expression of a human antibody and the respective antigen in the diatom Phaeodactylum tricornutum. PLoS ONE 6:e28424. doi: 10.1371/journal.pone.0028424
Jacob, S. S., Cherian, S., Sumithra, T. G., Raina, O. K., and Sankar, M. (2013). Edible vaccines against veterinary parasitic diseases-current status and future prospects. Vaccine 31, 1879–1885. doi: 10.1016/j.vaccine.2013.02.022
Jones, C. S., Luong, T., Hannon, M., Tran, M., Gregory, J. A., Shen, Z., et al. (2013). Heterologous expression of the C-terminal antigenic domain of the malaria vaccine candidate Pfs48/45 in the green algae Chlamydomonas reinhardtii. Appl. Microbiol. Biotechnol. 97, 1987–1995. doi: 10.1007/s00253-012-4071-7
Khan, I., Twyman, R. M., Arcalis, E., and Stoger, E. (2012). Using storage organelles for the accumulation and encapsulation of recombinant proteins. Biotechnol. J. 7, 1099–1108. doi: 10.1002/biot.201100089
Kwon, K. C., Verma, D., Singh, N. D., Herzog, R., and Daniell, H. (2013). Oral delivery of human biopharmaceuticals, autoantigens and vaccine antigens bioencapsulated in plant cells. Adv. Drug Deliv. Rev. 65, 782–799. doi: 10.1016/j.addr.2012.10.005
Lossl, A. G., and Waheed, M. T. (2011). Chloroplast-derived vaccines against human diseases: achievements, challenges and scopes. Plant Biotechnol. J. 9, 527–539. doi: 10.1111/j.1467-7652.2011.00615.x
Manuell, A. L., Beligni, M. V., Elder, J. H., Siefker, D. T., Tran, M., Weber, A., et al. (2007). Robust expression of a bioactive mammalian protein in Chlamydomonas chloroplast. Plant Biotechnol. J. 5, 402–412. doi: 10.1111/j.1467-7652.2007.00249.x
Mason, H.S., and Herbst-Kralovetz, M. M. (2012). “Plant-derived antigens as mucosal vaccines,” in Mucosal Vaccines: Modern Concepts, Strategies, and Challenges, ed. P. A. Kozlowski (Berlin: Springer-Verlag Berlin), 101–120. doi: 10.1007/82_2011_158
Rasala, B. A., Muto, M., Lee, P. A., Jager, M., Cardoso, R. M., Behnke, C. A., et al. (2010). Production of therapeutic proteins in algae, analysis of expression of seven human proteins in the chloroplast of Chlamydomonas reinhardtii. Plant Biotechnol. J. 8, 719–733. doi: 10.1111/j.1467-7652.2010.00503.x
Rasala, B. A., Muto, M., Sullivan, J., and Mayfield, S. P. (2011). Improved heterologous protein expression in the chloroplast of Chlamydomonas reinhardtii through promoter and 5’ untranslated region optimization. Plant Biotechnol. J. 9, 674–683. doi: 10.1111/j.1467-7652.2011.00620.x
Rosales-Mendoza, S., Govea-Alonso, D. O., Monreal-Escalante, E., Fragoso, G., and Sciutto, E. (2012a). Developing plant-based vaccines against neglected tropical diseases: where are we? Vaccine 31, 40–48. doi: 10.1016/j.vaccine.2012.10.094
Rosales-Mendoza, S., Rubio-Infante, N., Govea-Alonso, D. O., and Moreno-Fierros, L. (2012b). Current status and perspectives of plant-based candidate vaccines against the human immunodeficiency virus (HIV). Plant Cell Rep. 31, 495–511. doi: 10.1007/s00299-011-1194-8
Soria-Guerra, R. E., Ramírez-Alonso, J. I., Ibáñez-Salazar, A., Govea-Alonso, D. O., Paz-Maldonado, L. M. T., Bañuelos-Hernández, B., et al. (2014). Expression of an HBcAg-based antigen carrying angiotensin II in Chlamydomonas reinhardtii as a candidate hypertension vaccine. Plant Cell Tissue Organ Cult. 116, 133–139. doi: 10.1007/s11240-013-0388-x
Sun, M., Qian, K. X., Su, N., Chang, H. Y., Liu, J. X., and Chen, G. F. (2003). Foot-and-mouth disease virus VP1 protein fused with cholera toxin B subunit expressed in Chlamydomonas reinhardtii chloroplast. Biotechnol. Lett. 25, 1087–1092. doi: 10.1023/A:1024140114505
Surzycki, R., Greenham, K., Kitayama, K., Dibal, F., Wagner, R., Rochaix, J. D., et al. (2009). Factors effecting expression of vaccines in microalgae. Biologicals 37, 133–138. doi: 10.1016/j.biologicals.2009.02.005
Tran, M., Zhou, B., Pettersson, P. L., Gonzalez, M. J., and Mayfield, S. P. (2009). Synthesis and assembly of a full-length human monoclonal antibody in algal chloroplasts. Biotechnol. Bioeng. 104, 663–673. doi: 10.1002/bit.22446
Wang, X., Brandsma, M., Tremblay, R., Maxwell, D., Jevnikar, A. M., Huner, N., et al. (2008). A novel expression platform for the production of diabetes-associated autoantigen human glutamic acid decarboxylase (hGAD65). BMC Biotechnol. 8:87. doi: 10.1186/1472-6750-8-87
Wigdorovitz, A., Carrillo, C., Dus Santos, M. J., Trono, K., Peralta, A., Gomez, M. C., et al. (1999). Induction of a protective antibody response to foot and mouth disease virus in mice following oral or parenteral immunization with alfalfa transgenic plants expressing the viral structural protein VP1. Virology 255, 347–353. doi: 10.1006/viro.1998.9590
Keywords: oral vaccines, recombinant subunit vaccines, microalgae, plant-produced vaccines, algal engineering
Citation: Specht EA and Mayfield SP (2014) Algae-based oral recombinant vaccines. Front. Microbiol. 5:60. doi: 10.3389/fmicb.2014.00060
Received: 28 November 2013; Paper pending published: 23 December 2013;
Accepted: 30 January 2014; Published online: 17 February 2014.
Edited by:Germán Leandro Rosano, Instituto de Biología Molecular y Celular de Rosario, Argentina
Reviewed by:Edward Rybicki, University of Cape Town, South Africa
Ruth Elena Soria-Guerra, Universidad Autónoma de San Luis Potosí, Mexico
Pal Maliga, Rutgers University, USA
Copyright © 2014 Specht and Mayfield. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Stephen P. Mayfield, California Center for Algae Biotechnology, University of California at San Diego, Bonner Hall 2150, MC 0368, 9500 Gilman Drive, La Jolla, CA 92093, USA e-mail: email@example.com